Madrigal Pharmaceuticals (MDGL) Equity Average (2011 - 2026)

Madrigal Pharmaceuticals (MDGL) has 16 years of Equity Average data on file, last reported at $573.1 million in Q1 2026.

• Equity Average for Q1 2026 came in at $573.1 million, down 21.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $573.1 million (down 21.77% YoY), and the FY2025 annual result was $678.5 million, up 17.02% from the prior year.
• Equity Average eased to $573.1 million in Q1 2026 per MDGL's latest filing, from $614.2 million in the prior quarter.
• Over five years, Equity Average peaked at $853.9 million in Q2 2024 and troughed at $47.1 million in Q3 2022.
• A 5-year average of $433.1 million and a median of $573.1 million in 2026 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2024: Equity Average sank 81.37% in 2022, then jumped 1199.57% in 2024.
• A 5-year view of Equity Average shows it stood at $104.0 million in 2022, then jumped by 105.51% to $213.8 million in 2023, then soared by 258.19% to $765.8 million in 2024, then fell by 19.79% to $614.2 million in 2025, then decreased by 6.7% to $573.1 million in 2026.
• Business Quant data shows MDGL's Equity Average at $573.1 million in Q1 2026, $614.2 million in Q4 2025, and $660.9 million in Q3 2025.